MX2018014425A - Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. - Google Patents
Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma.Info
- Publication number
- MX2018014425A MX2018014425A MX2018014425A MX2018014425A MX2018014425A MX 2018014425 A MX2018014425 A MX 2018014425A MX 2018014425 A MX2018014425 A MX 2018014425A MX 2018014425 A MX2018014425 A MX 2018014425A MX 2018014425 A MX2018014425 A MX 2018014425A
- Authority
- MX
- Mexico
- Prior art keywords
- pro
- diseases
- neutrophil elastase
- human neutrophil
- inhibitory activity
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title abstract 2
- 239000000816 peptidomimetic Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 230000002849 elastaseinhibitory effect Effects 0.000 title 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 3
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 abstract 3
- 102000052502 human ELANE Human genes 0.000 abstract 3
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000008249 pharmaceutical aerosol Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000037581 Persistent Infection Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención se refiere a aerosoles farmacéuticos que comprenden una ß-horquilla peptidomimética de fórmula ciclo (-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-), o una sal farmacéuticamente aceptable del mismo, que tiene actividad inhibidora contra elastasa de neutrófilo humana. Además, se refiere a composiciones farmacéuticas sólidas o líquidas y kits para preparar y administrar tales aerosoles. La invención se puede utilizar para la prevención, manejo o tratamiento de enfermedades pulmonares, tal como la deficiencia de antitripsina alfa-1 (AATD), fibrosis quística (CF), bronquiactasia fibrosa no quística (NCFB) o enfermedad pulmonar obstructiva crónica (COPD), o infecciones, o enfermedades o afecciones de los pulmones, que son mediadas o que resultan de la actividad de la elastasa de neutrófilo humana. Por lo tanto, la invención se refiere además a una composición farmacéutica o un aerosol farmacéutico que comprende el compuesto activo ciclo (-OctG-Glu-Thr-Ala-Ser-Ile-Pro -Pro-Gln-Lys-Tyr-DPro-Pro-), o cualquier sal farmacéuticamente aceptable del mismo, para uso en un método para la prevención, manejo o tratamiento de enfermedades o afecciones de los pulmones que son mediadas o que resultan de la actividad de la elastasa de neutrófilo en un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020210 | 2016-05-31 | ||
| PCT/EP2017/025156 WO2017207117A1 (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014425A true MX2018014425A (es) | 2019-03-28 |
Family
ID=56108445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014425A MX2018014425A (es) | 2016-05-31 | 2017-05-31 | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. |
| MX2018014752A MX393629B (es) | 2016-05-31 | 2017-05-31 | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014752A MX393629B (es) | 2016-05-31 | 2017-05-31 | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11235023B2 (es) |
| EP (2) | EP3463281B1 (es) |
| JP (4) | JP7544466B2 (es) |
| KR (2) | KR102511284B1 (es) |
| CN (3) | CN109195580A (es) |
| AU (2) | AU2017273507B2 (es) |
| BR (2) | BR112018074551B1 (es) |
| CA (2) | CA3024521C (es) |
| CL (2) | CL2018003390A1 (es) |
| DK (2) | DK3463281T3 (es) |
| EA (2) | EA039603B1 (es) |
| ES (2) | ES2927948T3 (es) |
| HR (2) | HRP20221194T1 (es) |
| HU (2) | HUE060393T2 (es) |
| IL (2) | IL263112B2 (es) |
| LT (2) | LT3463281T (es) |
| MA (2) | MA45168A (es) |
| MX (2) | MX2018014425A (es) |
| PH (2) | PH12018502522A1 (es) |
| PL (2) | PL3463281T3 (es) |
| PT (2) | PT3463281T (es) |
| RS (2) | RS63622B1 (es) |
| SG (3) | SG10202113280XA (es) |
| SM (2) | SMT202200405T1 (es) |
| UA (2) | UA125899C2 (es) |
| WO (2) | WO2017207118A1 (es) |
| ZA (2) | ZA201807773B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3463281T3 (da) * | 2016-05-31 | 2022-09-26 | Spexis Ag | Beta-hårnåls peptidomimetic med elastase hæmmende aktivitet og aerosol doseringsformer heraf |
| BR112022003226A2 (pt) * | 2019-08-23 | 2022-08-16 | Ph Pharma Co Ltd | Uso de um inibidor de elastase de neutrófilos em doença pulmonar |
| WO2021155087A1 (en) * | 2020-01-30 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Methods of treatment for alpha-1 antitrypsin deficiency |
| JP7732999B2 (ja) | 2020-04-03 | 2025-09-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | アルファ１－アンチトリプシンのモジュレーター |
| EP4247338A2 (en) * | 2020-11-23 | 2023-09-27 | Spexis AG | Compositions of a beta-hairpin peptidomimetic and aerosol dosage forms thereof |
| CN116421704A (zh) * | 2023-02-20 | 2023-07-14 | 成都佩德生物医药有限公司 | 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1304118A3 (en) * | 1996-11-01 | 2004-01-14 | XOMA Technology Ltd. | Therapeutic uses and formulations for BPI protein products. |
| WO2006079019A2 (en) * | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion |
| JP4896892B2 (ja) | 2005-02-17 | 2012-03-14 | ポリファー リミテッド | プロテアーゼ阻害活性を有するテンプレート固定β−ヘアピンペプチド擬似体 |
| EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| US7973005B2 (en) * | 2006-02-09 | 2011-07-05 | Kamada Ltd. | Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases |
| PT1991201T (pt) * | 2006-02-10 | 2018-06-12 | Pari Pharma Gmbh | Antibióticos nebulizados para terapia de inalação |
| WO2008025560A1 (en) * | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
| EP1927373B1 (en) * | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
| EP2567691B1 (en) * | 2011-09-12 | 2014-12-24 | Meiji Seika Pharma Co., Ltd. | Aqueous compositions comprising arbekacin |
| WO2015096672A1 (zh) | 2013-12-23 | 2015-07-02 | 石家庄铁道大学 | 测试装置 |
| US10340848B2 (en) | 2013-12-26 | 2019-07-02 | Kaneka Corporation | I-V measurement device for solar cell, manufacturing method for solar cell, and solar cell module |
| MX389053B (es) * | 2013-12-27 | 2025-03-20 | Polyphor Ag | Peptidomimeticos de horquilla beta como inhibidores de elastasa selectivos. |
| EA034910B1 (ru) * | 2013-12-27 | 2020-04-06 | Полифор Аг | Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы |
| DK3463281T3 (da) * | 2016-05-31 | 2022-09-26 | Spexis Ag | Beta-hårnåls peptidomimetic med elastase hæmmende aktivitet og aerosol doseringsformer heraf |
-
2017
- 2017-05-31 DK DK17733738.3T patent/DK3463281T3/da active
- 2017-05-31 PL PL17733738.3T patent/PL3463281T3/pl unknown
- 2017-05-31 BR BR112018074551-0A patent/BR112018074551B1/pt not_active IP Right Cessation
- 2017-05-31 EP EP17733738.3A patent/EP3463281B1/en active Active
- 2017-05-31 SM SM20220405T patent/SMT202200405T1/it unknown
- 2017-05-31 CA CA3024521A patent/CA3024521C/en active Active
- 2017-05-31 RS RS20220923A patent/RS63622B1/sr unknown
- 2017-05-31 AU AU2017273507A patent/AU2017273507B2/en not_active Ceased
- 2017-05-31 CA CA3024522A patent/CA3024522C/en active Active
- 2017-05-31 MA MA045168A patent/MA45168A/fr unknown
- 2017-05-31 JP JP2018562549A patent/JP7544466B2/ja active Active
- 2017-05-31 MX MX2018014425A patent/MX2018014425A/es unknown
- 2017-05-31 MX MX2018014752A patent/MX393629B/es unknown
- 2017-05-31 SG SG10202113280XA patent/SG10202113280XA/en unknown
- 2017-05-31 CN CN201780033187.7A patent/CN109195580A/zh active Pending
- 2017-05-31 HR HRP20221194TT patent/HRP20221194T1/hr unknown
- 2017-05-31 CN CN202211636345.7A patent/CN116159024A/zh active Pending
- 2017-05-31 LT LTEPPCT/EP2017/025157T patent/LT3463281T/lt unknown
- 2017-05-31 EP EP17733737.5A patent/EP3463280B1/en active Active
- 2017-05-31 LT LTEPPCT/EP2017/025156T patent/LT3463280T/lt unknown
- 2017-05-31 IL IL263112A patent/IL263112B2/en unknown
- 2017-05-31 SG SG11201810138XA patent/SG11201810138XA/en unknown
- 2017-05-31 KR KR1020187036055A patent/KR102511284B1/ko active Active
- 2017-05-31 US US16/305,518 patent/US11235023B2/en active Active
- 2017-05-31 UA UAA201812929A patent/UA125899C2/uk unknown
- 2017-05-31 WO PCT/EP2017/025157 patent/WO2017207118A1/en not_active Ceased
- 2017-05-31 HU HUE17733738A patent/HUE060393T2/hu unknown
- 2017-05-31 EA EA201892818A patent/EA039603B1/ru unknown
- 2017-05-31 HU HUE17733737A patent/HUE060119T2/hu unknown
- 2017-05-31 MA MA045167A patent/MA45167A/fr unknown
- 2017-05-31 DK DK17733737.5T patent/DK3463280T3/da active
- 2017-05-31 EA EA201892819A patent/EA201892819A1/ru unknown
- 2017-05-31 SG SG11201810137UA patent/SG11201810137UA/en unknown
- 2017-05-31 JP JP2018562561A patent/JP7286319B6/ja active Active
- 2017-05-31 PL PL17733737.5T patent/PL3463280T3/pl unknown
- 2017-05-31 AU AU2017273508A patent/AU2017273508B2/en not_active Ceased
- 2017-05-31 PT PT177337383T patent/PT3463281T/pt unknown
- 2017-05-31 US US16/305,714 patent/US11235024B2/en active Active
- 2017-05-31 KR KR1020187036054A patent/KR102480800B1/ko active Active
- 2017-05-31 ES ES17733737T patent/ES2927948T3/es active Active
- 2017-05-31 BR BR112018074532-4A patent/BR112018074532B1/pt not_active IP Right Cessation
- 2017-05-31 IL IL263114A patent/IL263114B2/en unknown
- 2017-05-31 WO PCT/EP2017/025156 patent/WO2017207117A1/en not_active Ceased
- 2017-05-31 CN CN201780033188.1A patent/CN109310613A/zh active Pending
- 2017-05-31 ES ES17733738T patent/ES2928050T3/es active Active
- 2017-05-31 PT PT177337375T patent/PT3463280T/pt unknown
- 2017-05-31 UA UAA201812930A patent/UA125900C2/uk unknown
- 2017-05-31 RS RS20220922A patent/RS63639B1/sr unknown
- 2017-05-31 HR HRP20221185TT patent/HRP20221185T1/hr unknown
- 2017-05-31 SM SM20220404T patent/SMT202200404T1/it unknown
-
2018
- 2018-11-19 ZA ZA2018/07773A patent/ZA201807773B/en unknown
- 2018-11-19 ZA ZA2018/07772A patent/ZA201807772B/en unknown
- 2018-11-28 CL CL2018003390A patent/CL2018003390A1/es unknown
- 2018-11-28 CL CL2018003391A patent/CL2018003391A1/es unknown
- 2018-11-29 PH PH12018502522A patent/PH12018502522A1/en unknown
- 2018-11-29 PH PH12018502521A patent/PH12018502521A1/en unknown
-
2021
- 2021-10-06 US US17/495,137 patent/US11844823B2/en active Active
-
2022
- 2022-01-04 JP JP2022000083A patent/JP2022078013A/ja active Pending
- 2022-10-20 JP JP2022168582A patent/JP2023017793A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502521A1 (en) | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof | |
| EP4548972A3 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| MY196599A (en) | Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| HK1247838A1 (zh) | 骨质疏松症的治疗 | |
| PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
| NZ708593A (en) | Novel pyrazole derivative | |
| JP2013520405A5 (es) | ||
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| WO2013112959A8 (en) | Antifibrotic compounds and uses thereof | |
| MD4369B1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| HRP20140707T1 (hr) | KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| WO2017178897A3 (en) | Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists | |
| WO2015048641A3 (en) | Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases | |
| WO2005120148A3 (en) | Compounds derived from lidocaine, pharmaceutical compositions, use and method of treatment, prevention or inhibition of diseases | |
| WO2018067638A3 (en) | High mobility group b1 protein inhibitors | |
| MX372705B (es) | Composición farmacéutica que contiene budesonida y formoterol | |
| CA3150236A1 (en) | COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CHRONIC OBSTRUCTIVE BRONCHO-PNEUMOPATHIES (COPD) | |
| WO2016013877A3 (en) | A novel compound isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the composition comprising the same for preventing or treating allergy disease, inflammatory disease, asthma or chronic obstructive pulmonary disease and the use thereof | |
| HK1217191A1 (zh) | 治療性化合物和其用途 | |
| HK1230969A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| TN2013000015A1 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor |